The LXBD Study is evaluating how safe an investigational medicine is and how effective it is at treating diabetic peripheral neuropathic foot pain in adults.

Participants are randomly assigned to 1 of 4 groups. Participants in 3 of the groups receive varying dosages of the investigational medicine, and those in the fourth group receive a placebo (a substance that looks like the investigational medicine but contains no active ingredients), both taken orally (by mouth).

The study involves up to 15 study visits—5 of which can be done over the phone—over the course of about 24 weeks after the initial screening period. Approximately 410 participants will be enrolled, and they may be compensated for travel and expenses.